Skip to content
Open access

The Impact of Psychobiotic Therapy on Anxiety and Depressive Symptoms in Patients with Post-COVID Syndrome—A Randomized, Double-Blind, Placebo-Controlled Trial

Aug 2026 · Metabolites · Vol 16, pp. 594 · 0 citations · 71 references
Medicine

TL;DR

Psychobiotic supplementation in individuals recovering from COVID-19 who exhibit anxiety and/or depressive symptoms led to mood improvement and a reduction in symptom severity, and it may serve as a supportive treatment.

Abstract

Background: Recovering from COVID-19 does not always lead to complete recovery, and many patients report symptoms of anxiety and depression. One potential mechanism behind these disorders is dysbiosis. The aim of this study was to evaluate the impact of psychobiotic therapy on the effectiveness of treating anxiety and depressive symptoms in individuals who had previously experienced COVID-19. Methods: This study was designed as a randomized, double-blind, placebo-controlled trial. A total of 62 participants were randomly allocated to one of two groups: a psychobiotic group (PG; 23 women, 9 men) receiving 3 × 109 CFU Lactobacillus helveticus and Bifidobacterium longum, or a control group (CG; 21 women, 9 men) receiving a placebo, for 6 weeks. Fifty-six participants finalized the study and were included in the analysis (28 per group). The severity of depressive and anxiety symptoms at baseline and after the intervention was assessed using validated self-assessment tools: the Hospital Anxiety and Depression Scale (HADS), the Generalized Anxiety Disorder 7-item scale (GAD-7), the Beck Depression Inventory (BDI), and the Hopkins Symptom Checklist (SCL-90). Additionally, the profile of selected short-chain fatty acids (SCFAs) in the stool was assessed. Results: Following the supplementation period, the PG showed significantly lower median levels of depression and anxiety compared to the CG, corresponding to a 57.2% reduction in anxiety severity (GAD-7) and a 50.9% reduction in depressive symptoms (BDI) (HADS—Depression and Anxiety, and GAD-7: p = 0.0001; BDI: p = 0.0003). Additionally, the prevalence of anxiety and depressive symptoms significantly decreased in the PG compared to the CG based on the HADS-A (p = 0.0044), GAD-7 (p = 0.0219), and BDI (p = 0.0011) scores. Among the measured SCFAs, only the butyric acid concentration in PG increased significantly during supplementation (baseline vs. follow-up—p = 0.0338) and was higher in PG than in CG at the study’s end (p = 0.0248). However, in the PG, changes in the concentrations of all analyzed acids correlated with a reduction in the severity of anxiety symptoms measured using the HADS-A. Conclusions: Psychobiotic supplementation in individuals recovering from COVID-19 who exhibit anxiety and/or depressive symptoms led to mood improvement and a reduction in symptom severity, and it may serve as a supportive treatment.

Read PDF

Similar papers

Sep 2026

Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis: A Single-Blind Feasibility Proof-of-Concept Trial.

BACKGROUND Depressive and anxiety symptoms are highly prevalent among patients with cancer and are associated with substantial reductions in quality of life. However, effective therapeutic options remain limited. Ayahuasca, a serotonergic psychedelic traditionally used in Amazonian ritual contexts, has shown rapid anti...

R. M. Maekawa, L. T. L. Guerra, Bianca Villanova et al. · 0 citations
Clinical trial Sep 2026

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind Trial.

Objective: Anxious distress is associated with poor outcomes in the treatment of major depressive disorder (MDD). This exploratory post hoc analysis utilized data from a phase 3 study to investigate adjunctive lumateperone 42 mg efficacy in patients with MDD with inadequate antidepressant therapy (ADT) response and anx...

Gary S. Sachs, S. Durgam, W. Earley et al. · 0 citations
Open access Sep 2026

722. Predictors of therapeutic response to LSD in anxiety: short- and long-term outcomes

Abstract Background Anxiety disorders are a major health burden and current treatment options yield unsatisfactory results. Psychedelics, such as lysergic acid diethylamide (LSD) that act via agonism on serotonin 2A receptors, have recently been shown to be effective in the treatment of anxiety symptoms. Aims & Objecti...

F. Holze, F. Müller, P. Gasser et al. · 0 citations
Open access Oct 2026

Esketamine’s therapeutic effect on anhedonia in adolescents: a post-hoc of a randomized controlled trial

Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients’ quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored. In this study, a prosp...

Qian-Qian Wu, Wei-Cheng Li, Zhan-Jie Luo et al. · 0 citations
Aug 2026

Effects of probiotic supplementation on sleep and psychological outcomes in adults with mild-to-moderate insomnia symptoms and work-related stress: A randomized, placebo-controlled, double-blind trial.

This study aimed to investigate the effects of the Cerebiome® probiotic supplement on mild to moderate insomnia symptoms associated with work-related stress. Using a randomized, placebo-controlled, double-blind, parallel design, adults aged 18-65 with mild to moderate insomnia symptoms but no diagnosis of mental disord...

S. Binda, N. Auclair-Ouellet, Ola Kassem et al. · 0 citations
Aug 2026

The Effect of Acupressure on Beta-Endorphin, Hypocretin, Cognition, and Patient-Reported Outcome Measures in Multiple Sclerosis Patients.

BACKGROUND Multiple sclerosis (MS) is associated with neurochemical alterations, cognitive impairment, and patient-reported symptoms that substantially affect quality of life. Although self-acupressure has shown promise for symptom management, its effects on neuropeptides and cognition remain unclear. This study aimed...

Şeyma Demir Erbaş, Elif Gencer Sendur, Dilek Yılmaz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.